@conference{c510ad49b5bd4f74aeaa31ee47ddd221,
title = "Determining argininosuccinate synthetase (ASS) expression in melanoma patients treated with arginine depleting therapy",
author = "Dinh, \{Vy T\}",
note = "10627 Background: In our phase II trial in advanced melanoma (ASCO 2010) with arginine depleting therapy using ADI-PEG20 (Polaris Pharmaceuticals), we found that response to therapy correlated with tumor expression of enzyme, ASS. Normal cells which possess ASS can recycle citrulline to arginine and hence evade cell death, whereas melanoma tumors lacking ASS do not.; American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 01-01-2014",
year = "2011",
language = "American English",
}